

| Variable | Phase II | | Phase II/III | | Phase III | | All Phases Total (n=143) |
|---------------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|--------------------------------|
| | Private (n=60) | Public (n=15) | Private (n=19) | Public (n=13) | Private (n=22) | Public (n=14) | |
| Disease area | 10 (17) | 4 (27) | 4 (21) | 6 (46) | 7 (32) | 4 (29) | 35 (24) |
| Oncology | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 1 (7) | 2 (1) |
| Stroke | 8 (13) | 1 (7) | 3 (16) | 1 (8) | 1 (5) | 1 (7) | 15 (10) |
| Mental health | 3 (5) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 0 (0) | 4 (3) |
| Dementia | 2 (3) | 2 (13) | 0 (0) | 0 (0) | 2 (9) | 2 (14) | 8 (6) |
| Cardiology | 9 (15) | 1 (7) | 3 (16) | 1 (8) | 1 (5) | 0 (0) | 15 (10) |
| Musculoskeletal | 3 (5) | 0 (0) | 3 (16) | 0 (0) | 1 (5) | 1 (7) | 8 (6) |
| Respiratory | 3 (5) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 1 (7) | 5 (3) |
| Immunodeficiency | 3 (5) | 2 (13) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 6 (4) |
| Primary care | 2 (3) | 0 (0) | 1 (5) | 0 (0) | 3 (14) | 0 (0) | 6 (4) |
| Diabetes | 9 (15) | 1 (7) | 1 (5) | 1 (8) | 1 (5) | 2 (14) | 15 (10) |
| Oral and gastroenterology | 2 (3) | 1 (7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (2) |
| HIV | 2 (3) | 1 (7) | 1 (5) | 1 (8) | 3 (14) | 1 (7) | 9 (6) |
| Learning difficulties | 2 (3) | 1 (7) | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 4 (3) |
| Other ¹ | 4 (7) | 2 (13) | 2 (11) | 2 (15) | 1 (5) | 0 (0) | 11 (8) |
| Stopping rules | 8 (13) | 7 (47) | 2 (11) | 1 (8) | 3 (14) | 2 (14) | 23 (16) |
| Efficacy | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| Safety | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 0 (0) | 1 (1) |
| Futility | 43 (72) | 5 (33) | 12 (63) | 4 (31) | 13 (59) | 4 (29) | 81 (57) |
| Efficacy/safety | 1 (2) | 1 (7) | 0 (0) | 2 (15) | 1 (5) | 1 (7) | 6 (4) |
| Efficacy/futility | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 1 (1) |
| Safety/futility | 8 (13) | 2 (13) | 4 (21) | 5 (38) | 5 (23) | 6 (43) | 30 (21) |
| Efficacy/safety/futility | | | | | | | |
| National or international | 26 (43) | 11 (73) | 4 (21) | 11 (85) | 6 (27) | 12 (86) | 70 (49) |
| National | 32 (53) | 4 (27) | 15 (79) | 2 (15) | 16 (73) | 2 (14) | 71 (50) |
| International | | | | | | | |

continued on next page

continued from previous page

| Variable | Phase II | | Phase II/III | | Phase III | | All Phases Total (n=143) |
|--------------------------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|--------------------------------|
| | Private (n=60) | Public (n=15) | Private (n=19) | Public (n=13) | Private (n=22) | Public (n=14) | |
| Unknown | 2 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1) |
| State of study ² | | | | | | | |
| Active, not recruiting | 0 (0) | 0 (0) | 0 (0) | 2 (15) | 0 (0) | 0 (0) | 2 (1) |
| Recruiting | 17 (28) | 12 (80) | 6 (32) | 8 (62) | 3 (14) | 5 (36) | 51 (36) |
| Ongoing after recruitment | 6 (10) | 0 (0) | 1 (5) | 0 (0) | 4 (18) | 1 (7) | 12 (8) |
| Completed | 30 (50) | 1 (7) | 7 (37) | 3 (23) | 9 (41) | 5 (36) | 55 (38) |
| Terminated after recruitment | 5 (8) | 2 (13) | 5 (26) | 0 (0) | 6 (27) | 3 (21) | 21 (15) |
| Terminated before enrolment | 2 (3) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (1) |
| Population | | | | | | | |
| < 16 | 3 (5) | 2 (13) | 3 (16) | 1 (8) | 1 (5) | 0 (0) | 10 (7) |
| ≥ 16 | 52 (87) | 11 (73) | 12 (63) | 9 (69) | 19 (86) | 13 (93) | 116 (81) |
| > 50 only ³ | 4 (7) | 1 (7) | 4 (21) | 1 (8) | 1 (5) | 1 (7) | 12 (8) |
| All ages | 1 (2) | 1 (7) | 0 (0) | 2 (15) | 1 (5) | 0 (0) | 5 (3) |
| Primary outcome(s) | | | | | | | |
| Binary | 8 (13) | 3 (20) | 0 (0) | 4 (31) | 5 (23) | 4 (29) | 24 (17) |
| Continuous | 47 (78) | 11 (73) | 16 (84) | 4 (31) | 9 (41) | 4 (29) | 91 (64) |
| Time to event | 1 (2) | 0 (0) | 2 (11) | 3 (23) | 6 (27) | 3 (21) | 15 (10) |
| Ordinal | 2 (3) | 1 (7) | 0 (0) | 2 (15) | 0 (0) | 1 (7) | 6 (4) |
| Categorical | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 2 (1) |
| Continuous and time to event | 0 (0) | 0 (0) | 1 (5) | 0 (0) | 1 (5) | 0 (0) | 2 (1) |
| Continuous and binary | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 1 (1) |
| Continuous, binary and time to event | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 2 (1) |
| Trial intervention | | | | | | | |
| Drug | 59 (98) | 10 (67) | 19 (100) | 7 (54) | 19 (86) | 9 (64) | 123 (86) |
| Device | 0 (0) | 2 (13) | 0 (0) | 2 (15) | 2 (9) | 4 (29) | 10 (7) |
| Diet | 0 (0) | 1 (7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (1) |
| Psychological | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 0 (0) | 1 (1) |
| Physiological | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 0 (0) | 1 (1) |

continued on next page

continued from previous page

| Variable | Phase II | | Phase II/III | | Phase III | | All Phases Total (n=143) |
|------------------------------------|-------------------|------------------|-------------------|------------------|-------------------|------------------|--------------------------------|
| | Private (n=60) | Public (n=15) | Private (n=19) | Public (n=13) | Private (n=22) | Public (n=14) | |
| Drug and device | 0 (0) | 1 (7) | 0 (0) | 1 (8) | 1 (5) | 0 (0) | 3 (2) |
| Education and diet | 0 (0) | 0 (0) | 0 (0) | 1 (8) | 0 (0) | 0 (0) | 1 (1) |
| Drug and diet | 1 (2) | 1 (7) | 0 (0) | 0 (0) | 0 (0) | 1 (7) | 3 (2) |
| Number of trial arms ⁴ | | | | | | | |
| 1 | 16 (27) | 8 (53) | 5 (26) | 9 (69) | 13 (59) | 11 (79) | 62 (43) |
| 2 | 14 (23) | 4 (27) | 7 (37) | 2 (15) | 6 (27) | 1 (7) | 34 (24) |
| 3 | 10 (17) | 3 (20) | 4 (21) | 0 (0) | 2 (9) | 0 (0) | 19 (13) |
| 4 | 9 (15) | 0 (0) | 2 (11) | 1 (8) | 1 (5) | 1 (7) | 14 (10) |
| ≥ 5 | 11 (18) | 0 (0) | 1 (5) | 1 (8) | 0 (0) | 1 (7) | 14 (10) |
| Duration of primary outcome (days) | 60 {76} | 120 {315} | 84 {88} | 365 {29} | 336 {214} | 88 {252} | 84 {224} |
| Sample size | 200 {178} | 138 {150} | 306 {667} | 300 {849} | 451 {534} | 1417 {2459} | 240 {368} |

Results presented as n (%) or median {IQR}.

¹ Other therapeutic areas include: detached placenta, gastric ulcers, venous thromboembolism, lower urinary tract symptoms, septic shock, visceral leishmaniasis, chronic abacterial prostatitis, anemia, primary visceral leishmaniasis, ulcer and pre-eclampsia.

² As of September 2014.

³ > 50 only trials not included in ≥ 16 category.

⁴ Excludes comparator arm. Number of arms in multi-arm multi-stage (MAMS) design taken to be the original starting number.